Article in Genes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors at 5 institutions in 3 countries.
Hafid O Al-HassiResearch Institute of Healthcare Science, Faculty of Science and Engineering, University of Wolverhampton, Wolverhampton WV1 1LY, UK.ORCID 0000-0002-5119-7793
Naser M AliInstitute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.ORCID 0000-0002-7824-5169
Hannah CookeResearch Institute of Healthcare Science, Faculty of Science and Engineering, University of Wolverhampton, Wolverhampton WV1 1LY, UK.
Shamini De SilvaResearch Institute of Healthcare Science, Faculty of Science and Engineering, University of Wolverhampton, Wolverhampton WV1 1LY, UK.
Anna T BriniLaboratory of Biotechnological Applications, IRCCS Orthopedic Institute Galeazzi, 20157 Milan, Italy.ORCID 0000-0002-7848-8099
Vaiyapuri SumathiDepartment of Musculoskeletal Pathology, University Hospital of Birmingham, Birmingham B15 2TT, UK.
Mark R MorrisResearch Institute of Healthcare Science, Faculty of Science and Engineering, University of Wolverhampton, Wolverhampton WV1 1LY, UK.
Stefania NiadaLaboratory of Biotechnological Applications, IRCCS Orthopedic Institute Galeazzi, 20157 Milan, Italy.ORCID 0000-0003-3655-9968
University of Wolverhampton · GBAdan Hospital · KWHeartlands Hospital · GBIstituto Ortopedico Galeazzi · ITUniversity of Milan · IT
Funding
Italian Ministry of Health Ricerca Corrente L4097 and L4135, IRCCS Istituto Ortopedico GaleazziKuwait Medical Genetics Centre (KMGC), Ministry of Health, KuwaitRotha Abraham Bequest, New Cross Hospital, Wolverhampton, UK
6 · The paper itself
Abstract
PubMed holds no abstract for this paper.
Indexed as
Bone NeoplasmsChondrosarcomaFibroblast Growth Factor-23OsteosarcomaSarcomaHumansFGF23 protein, humanFibroblast Growth Factor-23dedifferentiated chondrosarcomaFGF23immunohistochemistrymolecular markerosteosarcomaundifferentiated high-grade pleomorphic sarcoma of bone
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
FGF23 Expression Is a Promising Immunohistochemical Diagnostic Marker for Undifferentiated Pleomorphic Sarcoma of Bone (UPSb). · full record | OpenQuestion